Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1

被引：4

作者：

Rossi, John M. ^{[1
]}

Galon, Jerome ^{[2
]}

Turcan, Sarah ^{[3
]}

Danan, Corinne ^{[3
]}

Locke, Frederick L. ^{[4
]}

Neelapu, Sattva S. ^{[5
]}

Miklos, David B. ^{[6
]}

Jacobson, Caron A. ^{[7
]}

Lekakis, Lazaros J. ^{[8
]}

Lin, Yi ^{[9
]}

Ghobadi, Armin ^{[10
]}

Go, William Y. ^{[1
]}

Bot, Adrian ^{[1
]}

机构：

[1] Kite, Santa Monica, CA USA

[2] UPMC Univ Paris, Sorbonne Univ, Univ Paris Descartes, INSERM, Paris, France

[3] HalioDx, Marseille, France

[4] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplantat, Tampa, FL USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Stanford Univ, Sch Med, Blood & Marrow Transplantat, Stanford, CA 94305 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Mayo Clin, Div Hematol, Rochester, MN USA

[10] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-LB-016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB-016

引用

页数：2

共 50 条

[41] Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).
Ahmed, Sairah
Furqan, Fateeha
Strati, Paolo
Westin, Jason
Fayad, Luis
Hagemeister, Frederick B.
Lee, Hun Ju
Iyer, Swaminathan Padmanabhan
Nair, Ranjit
Nastoupil, Loretta J.
Parmar, Simrit
Rodriguez, Maria Alma
Samaniego, Felipe
Steiner, Raphael
Wang, Michael
Pinnix, Chelsea Camille
Flowers, Christopher
Horowitz, Sandra B.
Hawkins, Misha
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[42] Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-up of the Pivotal Zuma-1 Trial
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Miklos, David
Jacobsen, Eric
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Timmerman, John
Reagan, Patrick
Bot, Adrian
Rossi, John
Navale, Lynn
Jiang, Yizhou
Aycock, Jeff
Elias, Meg
Wiezorek, Jeff
Go, William Y.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S66 - S67
[43] Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Miklos, David B.
Jacobsen, Eric D.
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Timmerman, John M.
Reagan, Patrick M.
Bot, Adrian
Rossi, John M.
Navale, Lynn
Jiang, Yizhou
Aycock, Jeff S.
Elias, Meg
Wiezorek, Jeffrey S.
Go, William Y.
BLOOD, 2017, 130
[44] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Topp, Max S.
van Meerten, Tom
Hout, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin W.
Avivi, Irit
Kuruvilla, John
Duehrsen, Ulrich
Chu, Rong
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
MOLECULAR THERAPY, 2020, 28 (04) : 577 - 577
[45] A standardized comparison of outcomes in patients (pts) with refractory, aggressive non-hodgkin Lymphoma (rNHL) from the SCHOLAR-1 analysis and the ZUMA-1 study of axicabtagene ciloleucel (axi-cel)
Neelapu, S. S.
Locke, F. L.
Bartlett, N. L.
Lekakis, L. J.
Reagan, P. M.
Miklos, D.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O.
Siddiqi, T.
Lin, Y.
Crump, M.
Kuruvilla, J.
Van den Neste, E.
Link, B. K.
Farooq, U.
Navale, L.
Go, W. Y.
Wiezorek, J.
Gisselbrecht, C.
ANNALS OF ONCOLOGY, 2017, 28
[46] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O.
Forcade, Edouard
Munoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron A.
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Zheng, Yan
Vardhanabhuti, Saran
Nater, Jenny
Shen, Rhine R.
Miao, Harry
Kim, Jenny
van Meerten, Tom
BLOOD, 2022, 140 : 10399 - 10401
[47] Dynamic changes in the tumor microenvironment from initial diagnosis through sequential therapies in patients with large B cell lymphoma undergoing axicabtagene ciloleucel (axi-cel) treatment
Mattie, Michael
Perbost, Regis
Auguste, Aurelie
Turcan, Sarah
Kim, Jenny J.
To, Christina
Nater, Jenny
Filosto, Simone
Shen, Rhine R.
Galon, Jerome
CANCER RESEARCH, 2024, 84 (07)
[48] Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)
Jacobson, Caron A.
Westin, Jason R.
Miklos, David B.
Herrera, Alex F.
Lee, Jennifer
Seng, Judy
Rossi, John M.
Sun, Jennifer
Dong, Jinghui
Roberts, Zachary J.
Vezan, Remus
Avanzi, Mauro P.
Locke, Frederick L.
CANCER RESEARCH, 2020, 80 (16)
[49] ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)
Kenderian, Saad S.
Oluwole, Olalekan O.
McCarthy, Philip L.
Reshef, Ran
Shiraz, Parveen
Ahmed, Omar
Le Gall, John
Nahas, Myrna
Tang, Lily
Neelapu, Sattva S.
BLOOD, 2020, 136
[50] The Phase 3, Randomized Study of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7
Schmitz, N.
Oluwole, O. O.
Bishop, M. R.
Gisselbrecht, C.
Gordon, L. I.
Kersten, M. J.
Maloney, D. G.
Caballero, M. D.
Kuruvilla, J.
Song, K. W.
Jacobson, C. A.
Nastoupil, L. J.
Riedell, P.
Jiang, Y.
Rossi, J. M.
Lee, L.
Cheng, P.
Locke, F. L.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 90 - 91

← 1 2 3 4 5 →